Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: A randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events

International Journal of Clinical Practice

Volumn 52, Issue 6, 1998, Pages

  Schaefer, R M ^a   Aldons, P M ^b   Burgess, E D ^b   Tilvis, R ^c   Girerd, X ^d   Singh, G P ^e   Rehn, L ^b   Morgan, T O ^f  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b University of Helsinki ^*

^c UNIVERSITY OF HELSINKI   (Finland)

^d HÔPITAL BROUSSAIS   (France)

^e NORTH SHORE HOSPITAL   (New Zealand)

^f UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; FELODIPINE; HYPERTENSIVE AGENT;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; EDEMA; FEMALE; HEADACHE; HOT FLUSH; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; VASCULAR DISEASE; VASODILATATION; VERTIGO;

EID: 3543113090     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Working Group on Primary Prevention of Hypertension. National High Blood Pressure Education Program Working Group Report on Primary Prevention of Hypertension. Arch Intern Med 1993; 153: 149-152.
2. European Working Party on high blood pressure in the elderly: mortality and morbidity results from the European Working Party on high blood pressure in the elderly trial. Lancet 1985; i: 1349-1354.
3. Dahlöf B, Lindholm LH, Hansson L et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (Stop-Hypertension). Lancet 1991; 338: 1281-1284.
4. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-3264.
5. MRC Working Party. Medical Research Council trial on treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405-412.
6. Zanchetti A, Chalmers JP, Arakawa K et al. The 1993 Guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. Blood Press 1993; 2: 86-100.
7. Ljung B. Vascular selectivity of felodipine. Drugs 1985; 29(suppl 2): 46-58.
8. Nordlander M, Abrahamsson T, Åkerblom B, Thalén P. In vivo/in vitro evaluation of vascular/myocardial selectivity of felodipine and amlodipine. 2nd International Symposium. Calcium Antagonists in Cardiovascular Care. Basel, Febraury 1991: 12.
9. Little WC, Cheng C-P, Elvelin L, Nordlander M. Vascular selective calcium entry blocker in the treatment of cardiovascular disorders: focus on felodipine. Cardiovasc Drug Ther 1995; 9: 657-663.
10. Todd PA, Faulds D. Felodipine: a review of the pharmacology and therapeutic use of the extended-release formulation in cardiovascular disorders. Drugs 1992; 44: 251-277.
11. Murdoch D, Heel RC. Amlodipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs 1991; 41: 478-505.
12. Hosie J, Mulder AW, for the Binational MC Study Group (UK and Holland). Antihypertensive effects of felodipine once daily given as monotherapy to elderly patients: a placebo comparison. J Hum Hypertens 1991; 5: 49-53.
13. Abernethy DR, Gutowska J, Lambert MD. Amlodipine in elderly hypertensive patients: pharmacokinetics and pharmacodynamics. J Cardiovasc Pharmacol 1988; 12(suppl 7): S67-S71.
14. Landahl SJ, Wiklund I, Forsby M, for the Swedish Multicentre Group. Quality of life and blood pressure control in the treatment of elderly hypertensive patients: a comparison between Plendil® and hydrochlorothiazide. Am J Hypertens 1994; 7: A156.
15. Koenig W, on behalf of the Multicentre Study Group. Efficacy and tolerability of felodipine and amlodipine in the treatment of mild to moderate hypertension. Drug Invest 1993; 5: 200-205.
16. Elliott HL, Meredith PA, Reid JL, Faulkner JK. A comparison of the disposition of single oral doses of amlodipine in young and elderly subjects. J Cardiovasc Pharmacol 1988; 12(suppl 7): S64-S66.
17. Blychert E, Edgar B, Elmfeldt D, Hedner T. A population study of the pharmacokinetics of felodipine. Br J Clin Pharmacol 1991; 31: 15-24.
18. Dupuy HJ. The Psychological General Well-Being (PGWB) Index. In: Wenger NK, Mattson ME, Furberg CF, Elinson J, Eds. Assessment of quality of life in clinical trials of cardiovascular therapies. New York: Le Jacq Cop, 1984: 170-183.
19. Dimenäs E, Dahlöf C, Olofsson B, Wiklund I. An instrument for quantifying subjective symptoms among untreated and treated hypertensives: development and documentation. J Clin Res Pharmacoepidemiol 1990; 4: 205-217.
20. Dimenäs E, Wallander AM, Svärdsudd K, Wiklund I. Aspects of quality of life on treatment with felodipine. Eur J Clin Pharmacol 1991; 40: 141-147.
21. Hjelmdal P, Wiklund I. Quality of Life on hypertensive drug therapy:scientific end-point or marketing exercise? J Hypertens 1992; 10: 1437-1446.
22. Osterloh I. The safety of amlodipine. Am Heart J 1989; 118: 1114-1120.
23. Elvelin L, Kennerfalk A, Elmfeldt D. Tolerability and safety of felodipine. Cardiovasc Drug Rev 1993; 11: 126-147.
24. Dimenäs E, Carlsson R, Glise H et al. Relevance of norm values as part of the documentation of Quality of Life instruments for use in upper gastrointestinal disease. Scand J Gastroenterol 1996; 31(suppl 221): 8-13.
25. Wiklund I, Dimenäs E, Partridge S. Effects of felodipine extended release on quality of life - an analysis of four clinical trials. Curr Ther Res 1995; 56: 81-94.